Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931021 · ClinicalTrials.gov registry record · Early Phase 1
Smoking Cessation Treatment for Head and Neck Cancer Patients
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT00931021 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 7 participants.
The verdict
NCT00931021, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a pilot research study examining the use of varenicline (Chantix) and the nicotine patch. The study is designed to find out whether one of these medications is more effective for smoking cessation with head and neck cancer patients. The study has three parts: 1) two intake sessions; 2) an 8-week treatment phase, and 3) a 3-month follow-up.
Interventions
- DRUG Nicotine Patch
- DRUG Varenicline (Chantix)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931021
The ClinicalTrials.gov registry entry for NCT00931021 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotine Patch is the first listed.
NCT00931021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00931021 about?
NCT00931021 is a clinical study titled "Smoking Cessation Treatment for Head and Neck Cancer Patients". This is a pilot research study examining the use of varenicline (Chantix) and the nicotine patch. The study is designed to find out whether one of these medications is more effective for smoking cessation with head and neck cancer patients. The study has three parts: 1) two intake sessions; 2) an 8-...
What is the current status of trial NCT00931021?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2009-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00931021?
The interventions under investigation include: Nicotine Patch (DRUG), Varenicline (Chantix) (DRUG).
Who is sponsoring clinical trial NCT00931021?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.